Email updates

Keep up to date with the latest news and content from Radiation Oncology and BioMed Central.

Open Access Highly Accessed Open Badges Research

Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study

Alan Katz12* and Josephine Kang23

Author Affiliations

1 Long Island Radiation Therapy, 6 Ohio Drive, New Hyde Park, NY, USA

2 Flushing Radiation Oncology Services, 40-20 Main Street, Flushing, NY, USA

3 New York University School of Medicine, 550 1st Ave, New York, NY 10016, USA

For all author emails, please log on.

Radiation Oncology 2014, 9:1  doi:10.1186/1748-717X-9-1

Published: 1 January 2014



Stereotactic Body Radiotherapy (SBRT) has excellent control rates for low- and intermediate-risk prostate carcinoma.The role of SBRT for high-risk disease remains less studied. We present long-term results on a cohort of patients with NCCN-defined high-risk disease treated with SBRT.


We retrospectively studied 97 patients treated as part of prospective trial from 2006–2010 with SBRT alone (n = 52) to dose of 35–36.25 Gy in 5 fractions, or pelvic radiation to 45 Gy followed by SBRT boost of 19–21 Gy in 3 fractions (n = 45). 46 patients received Androgen Deprivation Therapy. Quality of life and bladder/bowel toxicity was assessed using the Expanded Prostate Index Composite (EPIC) and RTOG toxicity scale.


Median followup was 60 months. 6-year biochemical disease-free survival (bDFS) was 69%. On multivariate analysis, only PSA remained significant (P < 0.01) for bDFS. Overall toxicity was mild, with 5% Grade 2–3 urinary and 7% Grade 2 bowel toxicity. Use of pelvic radiotherapy was associated with significantly higher bowel toxicity (P = .001). EPIC scores declined for the first six months and then returned towards baseline.


SBRT appears to be a safe and effective treatment for high-risk prostate carcinoma. Our data suggests that SBRT alone may be the optimal approach. Further followup and additional studies is required to corroborate our results.

Prostate cancer; Stereotactic radiotherapy; High-risk